02:28 PM EDT, 05/06/2025 (MT Newswires) -- CorMedix ( CRMD ) shares were up over 20% in recent trading on Tuesday after its Q1 net income and revenue surpassed analysts' consensus.

The company reported Q1 results swung to net income Tuesday of $0.30 per diluted share, from a loss of $0.25 a year earlier.

Analysts polled by FactSet expected EPS of $0.26.

Revenue for the quarter ended March 31 was $39.1 million.

Analysts surveyed by FactSet expected $36.9 million.

CorMedix ( CRMD ) expects to be at the high-end of the previously announced first half net sales guidance of $62 million to $70 million.

As of March 31, the company said it had $77.5 million in cash and/or cash equivalents on hand, and expected it could fund operations for at least 12 months from the issuance of its quarterly report on From 10-Q.

Price: 10.92, Change: +1.89, Percent Change: +20.87